2024
Herpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study
Tunnicliffe L, Weil R, Breuer J, Rodriguez‐Barradas M, Smeeth L, Rentsch C, Warren‐Gash C. Herpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study. Movement Disorders 2024, 39: 438-444. PMID: 38226430, PMCID: PMC10922272, DOI: 10.1002/mds.29701.Peer-Reviewed Original ResearchConceptsUS Department of Veterans AffairsCohort studyRisk of incident PDDepartment of Veterans AffairsCox proportional hazards regressionIncident Parkinson's diseaseAssociated with increased riskHistory of HZMatched cohort studyProportional hazards regressionRisk of PDHerpes zosterIncident PDRisk of incident Parkinson's diseaseVeterans AffairsIncident HZUS veteransPD overallHazards regressionPD riskParkinson's diseaseIncreased riskMatched individualsUS DepartmentAssociated with Parkinson's disease
2023
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants
Wang A, Shen J, Rodriguez A, Saunders E, Chen F, Janivara R, Darst B, Sheng X, Xu Y, Chou A, Benlloch S, Dadaev T, Brook M, Plym A, Sahimi A, Hoffman T, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuerêdo J, Muir K, Ito S, Liu X, Uchio Y, Kubo M, Kamatani Y, Lophatananon A, Wan P, Andrews C, Lori A, Choudhury P, Schleutker J, Tammela T, Sipeky C, Auvinen A, Giles G, Southey M, MacInnis R, Cybulski C, Wokolorczyk D, Lubinski J, Rentsch C, Cho K, Mcmahon B, Neal D, Donovan J, Hamdy F, Martin R, Nordestgaard B, Nielsen S, Weischer M, Bojesen S, Røder A, Stroomberg H, Batra J, Chambers S, Horvath L, Clements J, Tilly W, Risbridger G, Gronberg H, Aly M, Szulkin R, Eklund M, Nordstrom T, Pashayan N, Dunning A, Ghoussaini M, Travis R, Key T, Riboli E, Park J, Sellers T, Lin H, Albanes D, Weinstein S, Cook M, Mucci L, Giovannucci E, Lindstrom S, Kraft P, Hunter D, Penney K, Turman C, Tangen C, Goodman P, Thompson I, Hamilton R, Fleshner N, Finelli A, Parent M, Stanford J, Ostrander E, Koutros S, Beane Freeman L, Stampfer M, Wolk A, Håkansson N, Andriole G, Hoover R, Machiela M, Sørensen K, Borre M, Blot W, Zheng W, Yeboah E, Mensah J, Lu Y, Zhang H, Feng N, Mao X, Wu Y, Zhao S, Sun Z, Thibodeau S, McDonnell S, Schaid D, West C, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel A, Drake B, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou Y, John E, Grindedal E, Maehle L, Khaw K, Ingles S, Stern M, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein B, Kerns S, Ostrer H, Teixeira M, Paulo P, Brandão A, Watya S, Lubwama A, Bensen J, Butler E, Mohler J, Taylor J, Kogevinas M, Dierssen-Sotos T, Castaño-Vinyals G, Cannon-Albright L, Teerlink C, Huff C, Pilie P, Yu Y, Bohlender R, Gu J, Strom S, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach R, Brenner H, Chen X, Holleczek B, Schöttker B, Klein E, Hsing A, Kittles R, Murphy A, Logothetis C, Kim J, Neuhausen S, Steele L, Ding Y, Isaacs W, Nemesure B, Hennis A, Carpten J, Pandha H, Michael A, De Ruyck K, De Meerleer G, Ost P, Xu J, Razack A, Lim J, Teo S, Newcomb L, Lin D, Fowke J, Neslund-Dudas C, Rybicki B, Gamulin M, Lessel D, Kulis T, Usmani N, Abraham A, Singhal S, Parliament M, Claessens F, Joniau S, Van den Broeck T, Gago-Dominguez M, Castelao J, Martinez M, Larkin S, Townsend P, Aukim-Hastie C, Bush W, Aldrich M, Crawford D, Srivastava S, Cullen J, Petrovics G, Casey G, Wang Y, Tettey Y, Lachance J, Tang W, Biritwum R, Adjei A, Tay E, Truelove A, Niwa S, Yamoah K, Govindasami K, Chokkalingam A, Keaton J, Hellwege J, Clark P, Jalloh M, Gueye S, Niang L, Ogunbiyi O, Shittu O, Amodu O, Adebiyi A, Aisuodionoe-Shadrach O, Ajibola H, Jamda M, Oluwole O, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Diop H, Gundell S, Roobol M, Jenster G, van Schaik R, Hu J, Sanderson M, Kachuri L, Varma R, McKean-Cowdin R, Torres M, Preuss M, Loos R, Zawistowski M, Zöllner S, Lu Z, Van Den Eeden S, Easton D, Ambs S, Edwards T, Mägi R, Rebbeck T, Fritsche L, Chanock S, Berndt S, Wiklund F, Nakagawa H, Witte J, Gaziano J, Justice A, Mancuso N, Terao C, Eeles R, Kote-Jarai Z, Madduri R, Conti D, Haiman C. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nature Genetics 2023, 55: 2065-2074. PMID: 37945903, PMCID: PMC10841479, DOI: 10.1038/s41588-023-01534-4.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesMulti-ancestry genome-wide association studyNovel risk variantsRisk variantsAssociation studiesProstate cancer genome-wide association studiesCancer genome-wide association studyGenome-wide discoveryProstate cancer susceptibility lociGenetic risk scoreCancer susceptibility lociEuropean ancestry menGenetic studiesSusceptibility lociNon-aggressive diseaseEffective risk stratificationAfrican ancestry menProstate cancer riskAncestry groupsProstate cancer casesRisk stratificationAfrican ancestryProstate cancerCancer casesCancer riskEvidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry
Chen F, Madduri R, Rodriguez A, Darst B, Chou A, Sheng X, Wang A, Shen J, Saunders E, Rhie S, Bensen J, Ingles S, Kittles R, Strom S, Rybicki B, Nemesure B, Isaacs W, Stanford J, Zheng W, Sanderson M, John E, Park J, Xu J, Wang Y, Berndt S, Huff C, Yeboah E, Tettey Y, Lachance J, Tang W, Rentsch C, Cho K, Mcmahon B, Biritwum R, Adjei A, Tay E, Truelove A, Niwa S, Sellers T, Yamoah K, Murphy A, Crawford D, Patel A, Bush W, Aldrich M, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas C, Stern M, Kote-Jarai Z, Govindasami K, Cook M, Chokkalingam A, Hsing A, Goodman P, Hoffmann T, Drake B, Hu J, Keaton J, Hellwege J, Clark P, Jalloh M, Gueye S, Niang L, Ogunbiyi O, Idowu M, Popoola O, Adebiyi A, Aisuodionoe-Shadrach O, Ajibola H, Jamda M, Oluwole O, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Mensah J, Diop H, Van Den Eeden S, Blanchet P, Fowke J, Casey G, Hennis A, Lubwama A, Thompson I, Leach R, Easton D, Preuss M, Loos R, Gundell S, Wan P, Mohler J, Fontham E, Smith G, Taylor J, Srivastava S, Eeles R, Carpten J, Kibel A, Multigner L, Parent M, Menegaux F, Cancel-Tassin G, Klein E, Andrews C, Rebbeck T, Brureau L, Ambs S, Edwards T, Watya S, Chanock S, Witte J, Blot W, Gaziano J, Justice A, Conti D, Haiman C. Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry. European Urology 2023, 84: 13-21. PMID: 36872133, PMCID: PMC10424812, DOI: 10.1016/j.eururo.2023.01.022.Peer-Reviewed Original Research
2022
Potentially inappropriate medication use by level of polypharmacy among US Veterans 49–64 and 65–70 years old
Guillot J, Rentsch CT, Gordon KS, Justice AC, Bezin J. Potentially inappropriate medication use by level of polypharmacy among US Veterans 49–64 and 65–70 years old. Pharmacoepidemiology And Drug Safety 2022, 31: 1056-1074. PMID: 35780391, PMCID: PMC9464694, DOI: 10.1002/pds.5506.Peer-Reviewed Original ResearchConceptsLevel of polypharmacyRace/ethnicityPIM prevalencePrevalence of PIMsInappropriate medication useElectronic health recordsCommon PIMsPharmacy fillsPROMPT criteriaInappropriate medicationsOlder patientsMedication usePsychotropic medicationsRefill recordsPolypharmacyPatientsVeterans AffairsMedicationsPrevalenceHealth recordsFiscal year 2016AgeMeaningful differencesSexTarget ageValidation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations
Chen F, Darst BF, Madduri RK, Rodriguez AA, Sheng X, Rentsch CT, Andrews C, Tang W, Kibel AS, Plym A, Cho K, Jalloh M, Gueye SM, Niang L, Ogunbiyi OJ, Popoola O, Adebiyi AO, Aisuodionoe-Shadrach OI, Ajibola HO, Jamda MA, Oluwole OP, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Mensah JE, Adjei AA, Diop H, Lachance J, Rebbeck TR, Ambs S, Gaziano JM, Justice AC, Conti DV, Haiman CA. Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations. ELife 2022, 11: e78304. PMID: 35801699, PMCID: PMC9322982, DOI: 10.7554/elife.78304.Peer-Reviewed Original ResearchConceptsProstate cancer riskPolygenic risk scoresProstate cancerCancer riskOdds ratioMillion Veteran ProgramRisk scoreRisk stratification toolAge-specific absolute risksAfrican ancestry menCancer odds ratiosVeterans Health AdministrationCase-control studyNonaggressive prostate cancerProstate Cancer FoundationAge-specific riskAssociation of PRSPRS categoriesRisk-stratified screeningVeteran ProgramNational Cancer InstituteEuropean ancestry menStratification toolAbsolute riskEffect modificationLong COVID burden and risk factors in 10 UK longitudinal studies and electronic health records
Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, Huggins CF, Kwong ASF, Silverwood RJ, Di Gessa G, Bowyer RCE, Northstone K, Hou B, Green MJ, Dodgeon B, Doores KJ, Duncan EL, Williams FMK, Steptoe A, Porteous D, McEachan R, Tomlinson L, Goldacre B, Patalay P, Ploubidis G, Katikireddi S, Tilling K, Rentsch C, Timpson N, Chaturvedi N, Steves C. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nature Communications 2022, 13: 3528. PMID: 35764621, PMCID: PMC9240035, DOI: 10.1038/s41467-022-30836-0.Peer-Reviewed Original ResearchConceptsLong COVIDRisk factorsCardio-metabolic parametersOverweight/obesityElectronic healthcare recordsCOVID-19Community-based individualsSelf-reported COVID-19Electronic health recordsLongitudinal study sampleProlonged symptomsCOVID-19 casesFemale sexDiagnostic codesWhite ethnicityUK longitudinal studyMental healthHealth recordsStudy sampleEHR dataLongitudinal studySymptomsHealthcare recordsSpring 2021BurdenOverall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform
Bhaskaran K, Rentsch CT, Hickman G, Hulme WJ, Schultze A, Curtis HJ, Wing K, Warren-Gash C, Tomlinson L, Bates CJ, Mathur R, MacKenna B, Mahalingasivam V, Wong A, Walker AJ, Morton CE, Grint D, Mehrkar A, Eggo RM, Inglesby P, Douglas IJ, McDonald HI, Cockburn J, Williamson EJ, Evans D, Parry J, Hester F, Harper S, Evans SJ, Bacon S, Smeeth L, Goldacre B. Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform. PLOS Medicine 2022, 19: e1003871. PMID: 35077449, PMCID: PMC8789178, DOI: 10.1371/journal.pmed.1003871.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsCOVID-19 hospitalisationGeneral population controlsCOVID-19 groupCOVID-19 survivorsHospital admissionHigh riskInfluenza hospitalisationsCause mortalityCohort studyInfluenza patientsPrimary careGeneral populationInitial infectionAcute coronavirus disease 2019Lower respiratory tract infectionsSevere COVID-19 outcomesLong-term adverse outcomesCOVID-19 hospital admissionsSpecific causesPopulation controlsCause-specific hospitalisationRespiratory tract infectionsCause-specific outcomesPotential risk factorsGeographic and temporal variation in racial and ethnic disparities in SARS-CoV-2 positivity between February 2020 and August 2021 in the United States
Ferguson JM, Justice AC, Osborne TF, Magid HSA, Purnell AL, Rentsch CT. Geographic and temporal variation in racial and ethnic disparities in SARS-CoV-2 positivity between February 2020 and August 2021 in the United States. Scientific Reports 2022, 12: 273. PMID: 34997001, PMCID: PMC8741774, DOI: 10.1038/s41598-021-03967-5.Peer-Reviewed Original Research
2021
OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic
Collaborative T, Curtis HJ, MacKenna B, Walker AJ, Croker R, Mehrkar A, Morton C, Bacon S, Hickman G, Inglesby P, Bates C, Evans D, Ward T, Cockburn J, Davy S, Bhaskaran K, Schultze A, Rentsch CT, Williamson E, Hulme W, Tomlinson L, Mathur R, Drysdale H, Eggo RM, Wong AY, Forbes H, Parry J, Hester F, Harper S, Douglas I, Smeeth L, Goldacre B. OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic. Open Heart 2021, 8: e001784. PMID: 34785588, PMCID: PMC8595296, DOI: 10.1136/openhrt-2021-001784.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsBlood CoagulationBlood Coagulation TestsCOVID-19Drug MonitoringDrug PrescriptionsDrug SubstitutionDrug UtilizationEnglandFactor Xa InhibitorsFemaleHumansMaleMiddle AgedPatient SafetyPractice Guidelines as TopicPractice Patterns, Physicians'Primary Health CareRetrospective StudiesRisk AssessmentRisk FactorsState MedicineWarfarinConceptsWarfarin patientsNational Health ServiceCOVID-19 pandemicNational guidanceCare home residencyINR test resultsRenal function testsFrequent blood testingSafety alertsRoutine clinical dataAtrial fibrillation diagnosisElevated INRMedication changesOral anticoagulantsAnticoagulant therapyCohort studyAppropriate patientsINR testsFunction testsBlood testingPrimary careClinical dataDOACPatientsWarfarinProtease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation
Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. Journal Of Hepatology 2021, 75: 1312-1322. PMID: 34333102, PMCID: PMC8604762, DOI: 10.1016/j.jhep.2021.07.021.Peer-Reviewed Original ResearchConceptsSevere hepatic dysfunctionBaseline FIB-4Acute liver injuryHepatic dysfunctionInhibitor-based treatmentHepatic decompensationFIB-4Liver injuryHigh riskDAA therapyHazard ratioAdvanced liver fibrosis/cirrhosisRisk of ALIProtease inhibitor-based regimensProtease inhibitor-based treatmentLiver fibrosis/cirrhosisInhibitor-based regimensHepatitis C infectionSevere liver dysfunctionFibrosis/cirrhosisInhibitor-based therapyAminotransferase elevationChronic HCVALT elevationC infectionRelationship Between Glycemia and Cognitive Function, Structural Brain Outcomes, and Dementia: A Mendelian Randomization Study in the UK Biobank.
Garfield V, Farmaki AE, Fatemifar G, Eastwood SV, Mathur R, Rentsch CT, Denaxas S, Bhaskaran K, Smeeth L, Chaturvedi N. Relationship Between Glycemia and Cognitive Function, Structural Brain Outcomes, and Dementia: A Mendelian Randomization Study in the UK Biobank. Diabetes 2021, 70: 2313-2321. PMID: 33632741, DOI: 10.2337/db20-0895.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiological Specimen BanksBlood GlucoseBrainCognitionDementiaDiabetes Mellitus, Type 2FemaleGenome-Wide Association StudyGlycated HemoglobinHumansMaleMemoryMendelian Randomization AnalysisMiddle AgedOrgan SizePolymorphism, Single NucleotidePrognosisReaction TimeRisk FactorsUnited KingdomWhite MatterConceptsWhite matter hyperintensity volumeType 2 diabetesHippocampal volumeAlzheimer's dementiaRisk of ADCognitive functionMendelian randomizationBrain structuresStructural brain outcomesGenetic instrumentsMR sensitivity analysesUK BiobankVisual memoryMendelian randomization studyIncident dementiaBrain outcomesDiabetes riskHyperintensity volumeMeasures of cognitionPeripheral glycemiaBidirectional Mendelian randomizationDiabetesRandomization studyCausal associationGlycemiaUK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records
Walker JL, Grint DJ, Strongman H, Eggo RM, Peppa M, Minassian C, Mansfield KE, Rentsch CT, Douglas IJ, Mathur R, Wong AYS, Quint JK, Andrews N, Bernal JL, Scott JA, Ramsay M, Smeeth L, McDonald HI. UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records. BMC Public Health 2021, 21: 484. PMID: 33706738, PMCID: PMC7948667, DOI: 10.1186/s12889-021-10427-2.Peer-Reviewed Original ResearchConceptsSevere COVID-19Health conditionsElectronic health recordsHigh riskRisk populationsCOVID-19Clinical Practice Research Datalink GOLDSevere COVID-19 diseaseSecondary care recordsChronic kidney diseaseHealth recordsChronic liver diseasePoint prevalence studyBinomial exact confidence intervalsOlder age groupsPublic health interventionsWorking-aged individualsCOVID-19 diseaseWorking-aged adultsUK prevalenceCurrent asthmaLiver diseaseCancer survivorsPoint prevalenceKidney diseaseHbA1c and brain health across the entire glycaemic spectrum
Garfield V, Farmaki A, Eastwood SV, Mathur R, Rentsch CT, Bhaskaran K, Smeeth L, Chaturvedi N. HbA1c and brain health across the entire glycaemic spectrum. Diabetes Obesity And Metabolism 2021, 23: 1140-1149. PMID: 33464682, PMCID: PMC8261644, DOI: 10.1111/dom.14321.Peer-Reviewed Original ResearchConceptsVascular dementiaHippocampal volumeGlycaemic spectrumBrain healthWMH volumeAlzheimer's dementiaAD riskCognitive declineWhite matter hyperintensity volumeIncident vascular dementiaLower WMH volumeHigher WMH volumeGreater hippocampal volumeBrain health outcomesLower hippocampal volumeUK Biobank cohortGlycaemic categoriesKnown diabetesAntihypertensive medicationsHbA1c levelsCause dementiaCertain cardiovascular drugsExcess riskNormoglycaemic individualsHyperintensity volumeUse of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts
Wong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, Brown JP, Rentsch CT, Williamson E, Drysdale H, Croker R, Bacon S, Hulme W, Bates C, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson L, Mathur R, Wing K, Forbes H, Eggo RM, Parry J, Hester F, Harper S, Evans SJ, Smeeth L, Douglas IJ, Goldacre B, Collaborative T. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Annals Of The Rheumatic Diseases 2021, 80: 943-951. PMID: 33478953, PMCID: PMC7823433, DOI: 10.1136/annrheumdis-2020-219517.Peer-Reviewed Original ResearchConceptsNon-steroidal anti-inflammatory drugsPrescribed non-steroidal anti-inflammatory drugsRheumatoid arthritis/osteoarthritisArthritis/osteoarthritisCurrent NSAID usersMultivariable-adjusted modelsAnti-inflammatory drugsNSAID prescriptionsNSAID usersGeneral populationCOVID-19Risk of deathNational Health Service EnglandRoutine therapeutic useRoutine clinical dataCohort studyCurrent useCox regressionClinical dataCohort analysisLower riskEvidence of differencesDeath dataTherapeutic useDeath
2020
HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform
Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, Eggo RM, Morton CE, Bacon SCJ, Inglesby P, Douglas IJ, Walker AJ, McDonald HI, Cockburn J, Williamson EJ, Evans D, Forbes HJ, Curtis HJ, Hulme WJ, Parry J, Hester F, Harper S, Evans SJW, Smeeth L, Goldacre B. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. The Lancet HIV 2020, 8: e24-e32. PMID: 33316211, PMCID: PMC7773630, DOI: 10.1016/s2352-3018(20)30305-2.Peer-Reviewed Original ResearchConceptsCOVID-19 deathsNational death registrationsPrimary care dataHazard ratioHIV infectionOpenSAFELY platformBlack ethnicityHealth Research Oxford Biomedical Research CentreElectronic primary care dataPopulation-based cohort analysisDeath registrationUK primary care dataCare dataLarge-scale population-based studyRetrospective cohort studyPrimary care recordsUK Medical Research CouncilPopulation-based studyRisk of deathHealth Data Research UKNon-black individualsNational InstituteCOVID-19 mortalityMedical Research CouncilBiomedical Research CentreDevelopment and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index
King JT, Yoon JS, Rentsch CT, Tate JP, Park LS, Kidwai-Khan F, Skanderson M, Hauser RG, Jacobson DA, Erdos J, Cho K, Ramoni R, Gagnon DR, Justice AC. Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index. PLOS ONE 2020, 15: e0241825. PMID: 33175863, PMCID: PMC7657526, DOI: 10.1371/journal.pone.0241825.Peer-Reviewed Original ResearchConceptsCharlson Comorbidity IndexVeterans Health AdministrationVACO IndexValidation cohortMedical administrative dataDevelopment cohortSARS-CoV-2 testing resultsMortality indexICD-10 diagnosis codesUS Veterans Health AdministrationSARS-CoV-2 infectionPre-existing medical conditionsCOVID-19 mortality riskPeripheral vascular diseaseCOVID-19 patientsCOVID-19 infectionCOVID-19 mortalitySARS-CoV-2Administrative dataLogistic regression modelsRace/ethnicityCohort subgroupsComorbidity indexOverall mortalityComorbid conditionsSafety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder
Rentsch CT, Morford KL, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2020, 44: 1807-1815. PMID: 32628784, PMCID: PMC7540277, DOI: 10.1111/acer.14408.Peer-Reviewed Original ResearchConceptsAlcohol use disorderMental statusRelative riskGabapentin exposureUse disordersICD-9 diagnostic codesAdverse neurologic effectsPotential medication interactionsAltered mental statusIncidence of fallsClear dose-response relationshipLarge clinical cohortDose-response relationshipRace/ethnicityUnexposed patientsHepatitis CAdverse eventsMedication interactionsExcess riskNeurologic effectsUS veteransDiagnostic codesIncidence rateClinical cohortHigh riskPolypharmacy in HIV: recent insights and future directions.
Edelman EJ, Rentsch CT, Justice AC. Polypharmacy in HIV: recent insights and future directions. Current Opinion In HIV And AIDS 2020, 15: 126-133. PMID: 31833963, PMCID: PMC7543953, DOI: 10.1097/coh.0000000000000608.Commentaries, Editorials and LettersConceptsSeverity of illnessInappropriate medicationsDrug interactionsActual adverse eventsSubstance useTotal drug burdenMechanism of injuryElectronic health recordsNonantiretroviral medicationsUpdate findingsMore medicationsAdverse eventsDrug burdenClinical managementPolypharmacyDirect biomarkerMedicationsModifiable mechanismsPWHSicker individualsHealth recordsStrong associationHIVInjuryIllness
2019
Polypharmacy, Hazardous Alcohol and Illicit Substance Use, and Serious Falls Among PLWH and Uninfected Comparators.
Womack JA, Murphy TE, Rentsch CT, Tate JP, Bathulapalli H, Smith AC, Bates J, Jarad S, Gibert CL, Rodriguez-Barradas MC, Tien PC, Yin MT, Gill TM, Friedlaender G, Brandt CA, Justice AC. Polypharmacy, Hazardous Alcohol and Illicit Substance Use, and Serious Falls Among PLWH and Uninfected Comparators. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 82: 305-313. PMID: 31339866, PMCID: PMC7176040, DOI: 10.1097/qai.0000000000002130.Peer-Reviewed Original ResearchConceptsIllicit substance useHazardous alcoholSerious fallsUninfected comparatorsMedication classesOpioid prescriptionsSubstance useHIV statusMuscle relaxantsRisk factorsVeterans Aging Cohort StudyAging Cohort StudyIllicit substance abuseUnconditional logistic regressionNon-ART medicationsHazardous alcohol useSubstance use/abuseCase-control designKey risk factorsUse/abuseCohort studyMedication countInjury codesDuration of observationBaseline dateMedical Intensive Care Unit Admission Among Patients With and Without HIV, Hepatitis C Virus, and Alcohol-Related Diagnoses in the United States
Rentsch CT, Tate JP, Steel T, Butt AA, Gibert CL, Huang L, Pisani M, Soo Hoo GW, Crystal S, Rodriguez-Barradas MC, Brown ST, Freiberg MS, Graber CJ, Kim JW, Rimland D, Justice AC, Fiellin DA, Crothers KA, Akgün KM. Medical Intensive Care Unit Admission Among Patients With and Without HIV, Hepatitis C Virus, and Alcohol-Related Diagnoses in the United States. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 80: 145-151. PMID: 30422912, PMCID: PMC6701630, DOI: 10.1097/qai.0000000000001904.Peer-Reviewed Original ResearchConceptsHepatitis C virusAlcohol-related diagnosesAdmission ratesMICU admissionAdmission riskC virusRelative riskIntensive care unit admission rateMedical intensive care unit admissionAge-adjusted admission ratesHCV mono-infected patientsIntensive care unit admissionVeterans Aging Cohort StudyHCV care providersCare unit admissionAging Cohort StudyAdjusted rate ratiosConfidence intervalsVeterans Health AdministrationUnhealthy alcohol useHIV monoHIV-/HCVUnit admissionCause hospitalizationHCV infection